Thermo Fisher Scientific (NYSE:TMO) Hits New 12-Month High – Should You Buy?

Thermo Fisher Scientific Inc. (NYSE:TMO)’s stock price hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $671.47 and last traded at $663.61, with a volume of 110382 shares. The stock had previously closed at $658.52.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TMO shares. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Citigroup downgraded Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a report on Wednesday, September 9th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price on the stock. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 28th. Finally, Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $624.64.

Thermo Fisher Scientific Trading Up 0.0%

The company’s 50 day simple moving average is $597.90 and its two-hundred day simple moving average is $525.13. The company has a market capitalization of $243.51 billion, a price-to-earnings ratio of 35.41, a P/E/G ratio of 2.76 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s quarterly revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the business posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. The trade was a 12.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock valued at $44,122,820 over the last quarter. Insiders own 0.33% of the company’s stock.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently bought and sold shares of the business. Andra AP fonden raised its stake in shares of Thermo Fisher Scientific by 25.3% during the 2nd quarter. Andra AP fonden now owns 72,457 shares of the medical research company’s stock worth $36,327,000 after buying an additional 14,643 shares during the period. Security National Bank of Sioux City Iowa IA increased its holdings in Thermo Fisher Scientific by 25.1% in the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 7,783 shares of the medical research company’s stock worth $3,902,000 after acquiring an additional 1,560 shares in the last quarter. Anchor Investment Management LLC raised its position in Thermo Fisher Scientific by 31.2% during the second quarter. Anchor Investment Management LLC now owns 8,232 shares of the medical research company’s stock worth $4,127,000 after acquiring an additional 1,960 shares during the period. ABS Direct Equity Fund LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at $251,000. Finally, Rench Wealth Management Inc. grew its position in shares of Thermo Fisher Scientific by 17.6% in the second quarter. Rench Wealth Management Inc. now owns 2,906 shares of the medical research company’s stock valued at $1,457,000 after purchasing an additional 434 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of scientific equipment, laboratory services and analytical technologies. The company serves pharmaceutical and biotechnology companies, clinical laboratories, academic and government institutions, industrial businesses and other research organizations.

Its products and services include laboratory instruments, analytical systems, reagents, consumables, software and related services. Thermo Fisher also provides laboratory supplies and equipment, bioproduction solutions, genetic analysis technologies, clinical diagnostics, specialty diagnostic products and contract research and manufacturing services through its laboratory services businesses.

The company was formed in 2006 through the merger of Thermo Electron Corporation and Fisher Scientific International.